Health Care·Biotechnology·$5.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.24 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.24 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook due to the lack of guidance. They emphasized their commitment to advancing clinical trials.
Management did not provide specific guidance for future quarters.
The company is focused on its ongoing clinical trials and product development.
Rhythm Pharmaceuticals reported a loss of $1.24 per share, which was below expectations, though no revenue figures were disclosed. The stock reacted negatively, dropping 0.5%, likely due to the absence of guidance and clarity on future performance. Investors may be concerned about the company's path forward without clear financial targets.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PHILLIPS 66
Jul 26, 2019